No Data
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
Top Gap Ups and Downs on Thursday: SNY, DEO, GOLD and More
New Additions to Roth MKM's ADR Portfolio for September
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.